Private equity gets serious about drug development
Venture capital has the brains, private equity has the books – can they make lots of money?
Diabetes prevention signal emerges for Farxiga
SGLT2 inhibitors primarily treat diabetes, with benefits also seen in heart and kidney diseases. Might they also help prevent diabetes in the first place?
Should gene therapy patients be asked to pay?
The price in value-based payment deals should by definition be justified, so why is patient cost-sharing part of the calculation? Spark covers this cost, but there is no…
Gene therapy: how much will it cost patients?
Bluebird Bio has pushed forward the conversation on how to make million-dollar treatments affordable for insurers, but biopharma and payers are ominously quiet about…
The FDA’s proposed changes to device regulation are thin on detail
The FDA has made a lot of noise about its plans to make medical devices safer. But these plans are somewhat amorphous; any meaningful steps would likely require…
For drug treatment decisions machine learning must be more than a black box
The industry has its work cut out to rebuild trust in the tech following doubts about one pioneer, IBM Watson.
How machines could mine forgotten data
Drug discovery is getting harder, and some companies are turning to machine learning to look for new targets.
Big pharma piles into machine learning, but what will it get out of it?
Big pharma is using machine learning to improve the drug development process – but can the tech live up to the hype?
The million-dollar question hanging over US research funding law
As drug prices climb, is it time to ask whether the landmark technology transfer law is a fair deal for US taxpayers?